DNTH NASDAQ
Dianthus Therapeutics, Inc.
1W: +5.0%
1M: -1.8%
3M: +80.8%
YTD: +125.9%
1Y: +369.0%
3Y: +724.6%
5Y: -49.4%
$86.48
-3.15 (-3.51%)
Weekly Expected Move ±5.1%
$77
$82
$86
$91
$95
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (46)
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
Dianthus Therapeutics GAAP EPS of -$0.85 beats by $0.23, revenue of $0.46M beats by $0.1M
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $738,844.16 in Stock
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 114,367 Shares
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Tango Therapeutics is the best performing healthcare stock in March
Dianthus rises as FDA agrees with proposed changes to lead program
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $3,559,646.18 in Stock
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells $10,016,587.82 in Stock
Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH
HC Wainwright Issues Negative Estimate for DNTH Earnings
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High Following Analyst Upgrade
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up Following Analyst Upgrade
Dianthus Therapeutics announces proposed $400 million public share offering
Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
12 Health Care Stocks Moving In Monday's Pre-Market Session
Dianthus Therapeutics Earnings Review: Q4 Summary
Dianthus Therapeutics GAAP EPS of -$1.43 misses by $0.34, revenue of $0.28M misses by $0.17M
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Citigroup Inc. Has $2.70 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?
Latham Group, Babcock & Wilcox, B&G Foods And Other Big Stocks Moving Higher On Wednesday
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last?
Dianthus Therapeutics, Inc. (DNTH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)